90 results about "S100A8" patented technology

The present invention provides methods and compositions suitable for treating inflammatory disorders such as allergy, asthma, artherosclerosis, autoimmune disease, infection, injury, meningitis, psoriasis, and transplant rejection. In particular, the present invention provides methods and compositions comprising human S100A8 and / or S100A9 for reducing inflammation.

The present invention relates to compounds and methods for modulating, reducing or inhibiting, inflammatory reactions in a patient. Particularly, inflammatory reactions that are targeted by the present invention are cell migration, secretion of toxic products and proteolysis at a site of inflammation. Reduction of inflammation manifestations and reactions occurs by using an anti-S100 polynucleotide or polypeptide inhibitor or antagonist, which is essentially targeted against S100A8, S100A9 or S100A12, alone or in combination with other inhibitors of chemokines or immune modulating products.

Studies have been made on a possibility that a bone-marrow-derived cell is recruited from an extracutaneous tissue into a skin graft during the process of adhesion of the skin graft to a biological tissue and therefore contributes to the regeneration of a skin tissue. As a result, the following facts 1) to 4) are found: 1) a large quantity of bone-marrow-derived cells are recruited into a skin graft; 2) the recruited bone-marrow-derived cells are differentiated into all of dermal fibroblasts, adipocytes, muscle cells, vascular endothelial cells and epidermal keratinocytes in the skin graft, and bone-marrow-derived mesenchymal stem cells are contained in the recruited bone-marrow-derived cells; 3) the substances which recruit the bone-marrow-derived mesenchymal stem cells from the peripheral blood into the skin graft are S100A8 and S100A9 which are released from a dead tissue in the skin graft; and 4) purified S100A8 and S100A9 can promote the migration of a mesenchymal stem cell which has been separated from a bone marrow and cultured.

The present invention provides methods and kits to obtain an early evaluation of mortality risk and help therapeutic decisions for patients in severe sepsis with two organ failures, for example for patients in septic shock. The invention is based on the measure of the level of S100A8 / A9 complex in plasma, since a level of S100A8 / A9 above a predetermined threshold is indicative of a bad prognosis and a level of S100A8 / A9 below said predetermined threshold is indicative of a good prognosis.

The current invention concerns the use of PIP or S100A8 for the generation of regulatory T cells. The current invention provides a method of generating regulatory T cells by contacting immature DC with PIP or S100A8 to produce tolerogenic DC and further contacting naïve T cells to the tolerogenic DC to produce regulatory T cells. The invention also concerns PIP protein where immature DC contacted with PIP produce tolerogenic DC that induce conversion of naïve T-cells into regulatory T cells. The invention also concerns S100A8 protein where immature DC contacted with S100A8 produce tolerogenic DC that induce conversion of naïve T-cells into regulatory T cells. The invention also provides methods for identification of factors secreted by iNKT cells that induce conversion of immature DC into tolerogenic DC. The subject invention also concerns using regulatory T cells for treatment and / or management of cancer or the diseases of the immune system.

Disclosed is an in vitro method for assessing whether a human patient suffering from periodontitis has mild periodontitis or advanced periodontitis. The method is based on the insight to determine a selection of three bio marker proteins. Accordingly, in a sample of saliva a patient suffering from periodontitis, the concentrations are measured of the proteins Pyruvate Kinase (PK) and at least twoof Haemoglobin-beta (Hb-beta), Haemoglobin-delta (Hb-delta), S100 calcium-binding protein A8 (S100A8) and S100 calcium-binding protein A9 (S100A9). Based on the concentrations as measured, a value reflecting the joint concentrations for said proteins is determined. The value is compared with a threshold value reflecting in the same manner the joint concentrations associated with advanced periodontitis. The comparison allows assessing whether the testing value is indicative of the presence of advanced periodontitis or of mild periodontitis in the patient. Thereby, typically, a testing value reflecting a joint concentration below the joint concentration reflected by the threshold value is indicative for mild periodontitis in the patient, and a testing value reflecting a joint concentration at or above the joint concentration reflected by the threshold value, is indicative for advanced periodontitis in the patient.